Calendario›HALO›Mitomycin C

Mitomycin C

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Ensayo de HALOZYME THERAPEUTICS, INC. en Cancer de vejiga.

Más ensayos de: Cáncer de vejiga.

Fase

Fase 1/2

Estado

Completado

Participantes

27

previstos

Centros

5

Fin del objetivo primario

ago 2009

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en mar 2006.

Qué mide

Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC (5 weeks (Week 2 to Week 6)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of this study is to explore a treatment that potentially enhances the delivery of chemotherapy to tumors in participants with superficial bladder cancer. The investigational medication to be studied is an enzyme called ChemophaseTM (recombinant human hyaluronidase, rHuPH20). Chemophase is being specifically developed for use with other anticancer drug to increase the local penetration of the anticancer drug for the treatment of superficial bladder cancer. In this study, Chemophase will be given in combination with mitomycin C directly into the bladder. Mitomycin C is an anti-tumor drug that is commonly used to treat superficial bladder cancer. It is envisioned that Chemophase with mitomycin C may potentially increase the local penetration of mitomycin C into remaining cancer cells following surgery to treat superficial bladder cancer.

Más ensayos de HALO

Todos los de HALO, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00318643), actualizada en sep 2021.